Doreen M. Higgins

971 total citations
36 papers, 754 citations indexed

About

Doreen M. Higgins is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Doreen M. Higgins has authored 36 papers receiving a total of 754 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 24 papers in Oncology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Doreen M. Higgins's work include Immunotherapy and Immune Responses (23 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Doreen M. Higgins is often cited by papers focused on Immunotherapy and Immune Responses (23 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Doreen M. Higgins collaborates with scholars based in United States, South Korea and Canada. Doreen M. Higgins's co-authors include Jennifer S. Childs, Mary L. Disis, Yushe Dang, Lupe G. Salazar, Andrew L. Coveler, James Waisman, Patricia A. Fintak, Corazon dela Rosa, Hailing Lu and John S. Link and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Doreen M. Higgins

35 papers receiving 732 citations

Peers

Countries citing papers authored by Doreen M. Higgins

Since Specialization

Citations

This map shows the geographic impact of Doreen M. Higgins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doreen M. Higgins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doreen M. Higgins more than expected).

Fields of papers citing papers by Doreen M. Higgins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doreen M. Higgins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doreen M. Higgins. The network helps show where Doreen M. Higgins may publish in the future.

Co-authorship network of co-authors of Doreen M. Higgins

This figure shows the co-authorship network connecting the top 25 collaborators of Doreen M. Higgins. A scholar is included among the top collaborators of Doreen M. Higgins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doreen M. Higgins. Doreen M. Higgins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer 2025 ·Vaccines ·William R. Gwin, Lupe G. Salazar, James Y. Dai, Doreen M. Higgins, Andrew L. Coveler, Jennifer S. Childs, (unknown), Yushe Dang, (unknown), Meredith Slota, (unknown), Mary L. Disis	1
2	A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer 2023 ·Clinical Cancer Research ·Mary L. Disis, Yushe Dang, Andrew L. Coveler, Jennifer S. Childs, Doreen M. Higgins, Ying Liu, (unknown), Sean Mackay, Lupe G. Salazar	5
3	Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer 2022 ·JAMA Oncology ·Mary L. Disis, Katherine A. Guthrie, Ying Liu, Andrew L. Coveler, Doreen M. Higgins, Jennifer S. Childs, Yushe Dang, Lupe G. Salazar	65
4	Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses 2021 ·Clinical Cancer Research ·Denise L. Cecil, John B. Liao, Yushe Dang, Andrew L. Coveler, Angela Shaulov Kask, Yi Yang, Jennifer S. Childs, Doreen M. Higgins, Mary L. Disis	11
5	Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates 2021 ·Journal for ImmunoTherapy of Cancer ·John B. Liao, William R. Gwin, Renata R. Urban, (unknown), Andrew L. Coveler, Doreen M. Higgins, Jennifer S. Childs, (unknown), Ron E. Swensen, Sasha E. Stanton, Anna V. Tinker, Tanya A. Wahl, (unknown), Kathryn F. McGonigle, James Y. Dai, Mary L. Disis, Barbara A. Goff	17
6	Rural Hispanic/Latino cancer patients’ perspectives on facilitators, barriers, and suggestions for advance care planning: A qualitative study 2021 ·Palliative & Supportive Care ·Eunjeong Ko, (unknown), Doreen M. Higgins, (unknown), (unknown)	6
7	Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer. 2018 ·Journal of Clinical Oncology ·William R. Gwin, Jennifer S. Childs, Doreen M. Higgins, (unknown), John B. Liao, Mary L. Disis	2
8	Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer 2017 ·Gynecologic Oncology ·John B. Liao, Ron E. Swensen, (unknown), (unknown), (unknown), (unknown), Leonard D’Amico, Jennifer S. Childs, Doreen M. Higgins, (unknown), Barbara A. Goff, Mary L. Disis	13
9	Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo 2016 ·Journal for ImmunoTherapy of Cancer ·Sasha E. Stanton, Janet F. Eary, (unknown), David A. Mankoff, Lupe G. Salazar, Doreen M. Higgins, Jennifer S. Childs, (unknown), Yushe Dang, Mary L. Disis	23
10	Elimination of IL-10–Inducing T-Helper Epitopes from an IGFBP-2 Vaccine Ensures Potent Antitumor Activity 2014 ·Cancer Research ·Denise L. Cecil, Gregory E. Holt, Kyong Hwa Park, Ekram Gad, (unknown), Jennifer S. Childs, Doreen M. Higgins, Mary L. Disis	38
11	HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers 2013 ·Cancer Immunology Immunotherapy ·Mary L. Disis, Yushe Dang, Andrew L. Coveler, (unknown), (unknown), Jennifer S. Childs, Patricia A. Fintak, Doreen M. Higgins, (unknown), James Waisman, Lupe G. Salazar	31
12	T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity 2013 ·Breast Cancer Research and Treatment ·Denise L. Cecil, Kyong Hwa Park, Ekram Gad, Jennifer S. Childs, Doreen M. Higgins, Stephen R. Plymate, Mary L. Disis	15
13	Community Reentry and Older Adult Offenders: Redefining Social Work Roles 2009 ·Journal of Gerontological Social Work ·Doreen M. Higgins, Margaret Severson	14
14	Phase 1 study of infusion of HER-2/neu specific T cells in patients with advanced stage HER-2/neu overexpressing cancers who have received a HER-2/neu vaccine (41.3) 2009 ·The Journal of Immunology ·Yushe Dang, Lupe G. Salazar, Andrew L. Coveler, James Waisman, Doreen M. Higgins, Jennifer S. Childs, (unknown), Meredith Slota, Mary L. Disis	1
15	Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer 2009 ·Journal of Clinical Oncology ·Mary L. Disis, Danelle R. Wallace, Theodore A. Gooley, Yushe Dang, Meredith Slota, Hailing Lu, Andrew L. Coveler, Jennifer S. Childs, Doreen M. Higgins, Patricia A. Fintak, Corazon dela Rosa, (unknown), John S. Link, James Waisman, Lupe G. Salazar	224
16	Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity 2008 ·Molecular Cancer Therapeutics ·Vivian Goodell, James Waisman, Lupe G. Salazar, (unknown), John S. Link, Andrew L. Coveler, Jennifer S. Childs, Patricia A. Fintak, Doreen M. Higgins, Mary L. Disis	42
17	Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity 2008 ·Breast Cancer Research and Treatment ·Andrew L. Coveler, Vivian Goodell, (unknown), Lupe G. Salazar, Patricia A. Fintak, Jennifer S. Childs, Doreen M. Higgins, Mary L. Disis	11
18	Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer 2008 ·Cancer Research ·Kyong Hwa Park, Ekram Gad, Vivian Goodell, Yushe Dang, (unknown), Doreen M. Higgins, (unknown), Jennifer S. Childs, Corazon dela Rosa, Mary L. Disis	53
19	Tumor Antigen–Specific T-Cell Expansion Is Greatly Facilitated byIn vivoPriming 2007 ·Clinical Cancer Research ·Yushe Dang, Keith L. Knutson, Vivian Goodell, Corazon dela Rosa, Lupe G. Salazar, Doreen M. Higgins, Jennifer S. Childs, Mary L. Disis	31
20	Tumor antigen specific T cell expansion is greatly facilitated by in vivo priming. 2006 ·Cancer Research ·Yushe Dang, Keith L. Knutson, Corazon dela Rosa, Vivian Goodell, Doreen M. Higgins, Jennifer S. Childs, Mary L. Disis	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact